Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy.

@article{An2012PosttreatmentPV,
  title={Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy.},
  author={She-juan An and Yi-sheng Huang and Zhi-Hong Chen and Jian Su and Yan Yang and Jian-guang Chen and Hong-hong Yan and Qiu-xiong Lin and Jinji Yang and Xue-ning Yang and Qing Sheng Zhou and Xuchao Zhang and Yi-Long Wu},
  journal={Medical oncology},
  year={2012},
  volume={29 2},
  pages={627-32}
}
We sought to find blood-based biomarkers that can be used to predict efficacy in advanced non-small cell lung cancer patients treated with bevacizumab plus chemotherapy. Blood was collected before treatment and after 6 weeks of therapy from patients who were participating in a phase 4 trial. Plasma vascular endothelial growth factor (VEGF) levels were evaluated by ELISA. A total of eight single nucleotide polymorphisms in four candidate genes were analyzed by PCR and sequencing. A total of 45… CONTINUE READING